Core Viewpoint - China Merchants China Fund (00133.HK) announced that its wholly-owned subsidiary, Shenzhen Tianzheng Investment Co., Ltd., has signed a share purchase agreement with Boryeong Technology (Shanghai) Co., Ltd. to invest 15 million RMB in its E-round financing [1] Company Overview - Boryeong Technology, established in November 2011, focuses on the research, development, production, sales, and technical services of brain-machine interface systems, positioning itself as a high-tech enterprise in mainland China [1] - The company aims to provide comprehensive solutions for innovative research in neuroscience and clinical diagnosis, treatment, and rehabilitation of neurological diseases [1] Technological Expertise - Boryeong Technology has accumulated significant technical reserves and development experience in the brain-machine interface field over the years [1] - Its products are applicable in various research fields, including neuroscience, psychology, human factors engineering, kinesiology, and management science, as well as in clinical medicine for diagnosing, treating, and rehabilitating neurological diseases [1] - The company's research achievements and technical capabilities have gained recognition from experts in the fields of neuroengineering and clinical medicine both domestically and internationally [1]
招商局中国基金(00133.HK)斥资1500万元参与脑机接口企业博睿康技术E轮融资